Docetaxel: Standard recommended dose of 100 mg/m2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy - A phase II single-center study

Journal of Clinical Oncology

Volumn 17, Issue 4, 1999, Pages 1127-1131

  Salminen, E ^a   Bergman, M ^a   Huhtala, S ^a   Ekholm, E ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOCETAXEL; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD CELL COUNT; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0032906161     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.4.1127     Document Type: Article

References (21)

1. Gasparini G, Pozza F, Harris A: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206-1219, 1993
2. Mouridsen H: Systemic therapy of advanced breast cancer. Drugs 44:17-28, 1992
3. Harris J, Morrow M, Bonadonna G: Cancer of the breast. In De Vita VT Jr, Hellman S, Rosenberg S (eds): Cancer: Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 1264-1332
4. Ravdin P: Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer. Semin Oncol 24:S10-18-S10-21, 1997 (suppl 10)
5. Bissery M, Vrignaud P, Lavelle F: Preclinical profile of docetaxel (Taxotere): Efficacy as a single agent and in combination. Semin Oncol 22:3-16, 1995 (6 suppl 13)
6. Vogel M, Hilsenbeck S, Depenbrock H, et al: Preclinical activity of Taxotere against freshly explanted clonogenic human tumour cells: Comparison with Taxol and conventional antineoplastic agents. Eur J Cancer 29A:2009-2014, 1993
7. Chevallier B, Fumoleau P, Kerbrat P, et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314-322, 1995
8. Hortobagyi G: Docetaxel: Today's results and tomorrow's promises. Oncology (Huntingt) 8:11-14, 1997 (8 suppl 8)
9. ten Bokkel Huinink WW, Prove AM, Piccart M. et al: A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer: A study of the EORTC Early Clinical Trials Group. Ann Oncol 5:527-532, 1994
10. World Health Organization: Handbook for Reporting Results of Cancer Treatment: WHO publication no. 48. Geneva, Switzerland, World Health Organization, 1979
11. Clemons M, Leahy M, Valle J, et al: Review of recent trials of chemotherapy for advanced breast cancer: The taxanes. Eur J Cancer 33:2183-2193, 1997
12. Trudeau M: First line treatment of metastatic breast cancer. Anticancer Drugs 7:9-12, 1996 (suppl 2)
13. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995
14. Archer CD, Lowdell C, Sinnett HD, et al: Docetaxel: Response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer. Eur J Cancer 34:816-819, 1998
15. Hainsworth J, Burris H, Erland J, et al: Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16:2164-2168, 1998
16. Bruno R, Hille D, Riva A, et al: Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-196, 1998
17. Adachi I, Watanabe T, Takshima S, et al: A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 73:210-216, 1996
18. 2 as first-line chemotherapy for patients with advanced breast cancer: Report of the Clinical Screening Group of the EORTC-European Organization for Research and Treatment of Cancer. Br J Cancer 74:650-656, 1996
19. Ratain M: Body-surface area as a basis for dosing of anticancer agents: Science, myth, or habit? J Clin Oncol 16:2297-2298, 1998
20. Bruno R, Olivares R, Berille E, et al: Alpha-1-acid glycoprotein is an independent predictor of efficacy and survival in NSCLC patients treated with docetaxel. Proceedings Am Soc Clin Oncol 16:471a, abstract 1812, 1998
21. Piccart M, Di Leo A: Future perspectives of docetaxel (Taxotere) in front-line therapy. Semin Oncol 24:S10-27-S10-33, 1997 (suppl 10)